Antiviral treatment initiation costs in chronic hepatitis C [8]

Gut

Volumn 54, Issue 1, 2005, Pages 172-173

  Siebert, U ^a   Wasem, J ^a   Rossol, S ^a   Sroczynski, G ^a   Aidelsburger, P ^a   Ravens Sieberer, U ^a   Kurth, B M ^a   Manns, M P ^a   McHutchison, J G ^a   Wong, J B ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; PEGINTERFERON; RIBAVIRIN;

ANTIVIRAL ACTIVITY; CHRONIC HEPATITIS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; HEPATITIS C; LETTER; LIVER BIOPSY; PATIENT CARE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR;

ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; DIAGNOSTIC TESTS, ROUTINE; GERMANY; HEALTH CARE COSTS; HEPATITIS C, CHRONIC; HUMANS;

EID: 19944401081     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (13)

1. Wong JB, Bennett WG, Koff RS, et al. Pre-treatment evaluation of chronic hepatitis C: Risks, benefits and costs. JAMA 1998;280:2088-93.
2. Siebert U, Sroczynski G, Rossol S, et al, German Hepatitis C Model (GEHMO) Group, International Hepatitis Interventional Therapy (IHIT) Group. Cost effectiveness of peginterferon alpha-2b plus ribavirin versus Interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003;52:425-32.
3. Younossi Z, Singer M, McHutchison J, et al. Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology 1999;30:1318-24.
4. Wong JB, Poynard T, Ling MH, et al. Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C. International Hepatitis Interventional Therapy Group. Am J Gastroenterol 2000;95:1524-30.
5. Shepherd J, Waugh N, Hewitson P. Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review. Health Technol Assess 2000;4:1-67.
6. Buti M, Casado MA, Fosbrook L, et al. Cost-effectiveness of combination therapy for naive patients with chronic hepatitis C. J Hepatol 2000;33:651-8.
7. Stein K, Rosenberg W, Wong J. Cost effectiveness of combination therapy for hepatitis C: a decision analytic model. Gut 2002;50:253-8.
8. Sennfält K, Reichard O, Hultkrantz R, et al. Cost-effectiveness of interferon alfa-2b with and without ribavirin as therapy for chronic hepatitis C in Sweden. Scand J Gastroenterol 2001;36:870-6.
9. Sagmeister M, Wong J, Mullhaupt B, et al. A pragmatic and cost-effective strategy of a combination therapy of Interferon alpha-2b and ribavirin for the treatment of chronic hepatitis C. Eur J Gastroenterol Hepatol 2001;13:483-38.
10. Einheitlicher Bewertungsmaßstab (EBM). Cologne: Deutscher Aerzte Verlag, 2001.
11. Anonymous. Annual repart of the Association of Private Health Insurers. Die private Krankenversicherung-Zahlenbericht 2001/2002, http://www.pkv.de, Verband der privaten Krankenversicherung e.V., 2002.
12. Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
13. Wong JB, Koff RS. Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis. Ann Intern Med 2000;133:665-75.